GlaxoSmithKline plc
http://www.gsk.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlaxoSmithKline plc
Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug
The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.
Roche Gives The Stage To A New Generation Of Cancer Drugs
With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- ABR Development
- Cellzome
- Corixa Corporation
- Fountain Acquisition Corporation
- Genelabs Technologies, Inc.
- GlycoVaxyn AG
- Human Genome Sciences, Inc.
- ID Biomedical Corporation
- Okairos AG
- PRAECIS Pharmaceuticals, Inc.
- Reliant Pharmaceuticals
- Sirtris Pharmaceuticals
- Sitari Pharmaceuticals, Inc.
- SmithKline Beecham
- Stiefel Laboratories, Inc.
- Tesaro, Inc.
- ViiV Healthcare